Melanotan II Risk Profile: Full Evidence Review
Melanocortin Blood Pressure
0 safety trials
Melanotan II has never undergone controlled human safety testing. Everything known about its risks comes from case reports and pharmacological inference.
Nelson et al., Clinical Toxicology, 2012
Nelson et al., Clinical Toxicology, 2012
View as imageMelanotan II is a synthetic cyclic heptapeptide that activates melanocortin receptors 1, 3, 4, and 5 without selectivity. It is sold through online vendors for skin tanning, appetite suppression, and sexual enhancement. It has never been approved for human use in any country. No controlled safety trial has ever been completed. Everything known about its risk profile comes from case reports, pharmacological inference from its receptor binding, and limited analytical studies of products sold on the unregulated market.
As the pillar article on Melanocortin Peptides and Blood Pressure: The Hypertensive Risk explains, MC4R activation drives sympathetic nervous system stimulation that raises blood pressure and heart rate. Melanotan II activates MC4R potently alongside three other melanocortin receptors, creating a pharmacological profile that combines cardiovascular, dermatological, neurological, and metabolic effects with no dose optimization for any single indication.
Key Takeaways
- A 2012 case report documented rhabdomyolysis and systemic toxicity following melanotan II injection, with elevated creatine kinase and sympathomimetic symptoms (Nelson et al., 2012)
- At least five melanoma cases have been reported in melanotan II users, though all patients had additional risk factors including fair skin and UV exposure (Hjuler et al., 2014)
- A 2025 case report linked melanotan II nasal spray use to oral mucosal malignant melanoma in a 22-year-old female (Yassin et al., 2025)
- Analytical testing of black market melanotan II products found variable purity and the presence of degradation products not characterized for safety (Mestria et al., 2021)
- MC4R activation by melanotan II produces the same sympathetic blood pressure increase documented in clinical MC4R agonist studies, but without any monitoring
- Melanotan II was originally developed at the University of Arizona in the 1990s for tanning research; the sexual arousal effects were discovered incidentally (Hadley, 2005)
Cardiovascular Risk
Melanotan II's cardiovascular risk derives directly from its MC4R agonism. Clinical studies of the approved MC4R agonist bremelanotide (which shares structural similarity with melanotan II) demonstrated transient systolic blood pressure increases of approximately 6 mmHg per dose. MC4R agonist testing in the NEJM showed systolic increases of 9.3 mmHg at maximum tolerated doses.
Melanotan II users typically inject 0.5-1.0 mg subcutaneously daily during "loading" phases and several times weekly for maintenance. Unlike bremelanotide (which is limited to one dose per 24 hours and contraindicated in uncontrolled hypertension), melanotan II use involves chronic daily dosing without cardiovascular screening, blood pressure monitoring, or dose adjustment.
Nelson et al. (2012) reported a case of systemic toxicity following melanotan II injection. The patient presented with symptoms consistent with sympathomimetic excess, including tachycardia and hypertension, alongside rhabdomyolysis (muscle breakdown with elevated creatine kinase) and renal dysfunction. The case demonstrated that melanotan II's MC4R-driven sympathetic activation can produce clinically dangerous cardiovascular and muscular effects.[1]
A separate case report documented renal infarction following melanotan II use. The proposed mechanism was sympathetically-mediated vasoconstriction leading to renal artery compromise. While single case reports cannot establish causation, the pharmacological mechanism (MC4R-driven sympathetic activation causing vasoconstriction) is consistent with the known biology.
Dermatological Risk: Melanoma and Nevi
The MC1R-Melanoma Connection
Melanotan II activates MC1R, the receptor responsible for melanin production in melanocytes. MC1R activation stimulates eumelanin synthesis (dark pigment), which is the desired tanning effect. However, MC1R signaling also stimulates melanocyte proliferation, and uncontrolled melanocyte proliferation is the hallmark of melanoma.
The relationship between melanotan II and melanoma risk is complicated by confounding: people who use melanotan II for tanning are disproportionately fair-skinned individuals who also use tanning beds and have extensive UV exposure. Both UV exposure and fair skin are independent melanoma risk factors.
Documented Melanoma Cases
Hjuler et al. (2014) reported a case of melanoma associated with melanotan II use and reviewed the existing literature. At the time of publication, at least five melanoma cases had been reported in melanotan II users. In every case, the patient had additional melanoma risk factors (fair skin phenotype, UV exposure history, and/or family history). The authors could not establish whether melanotan II was a causative factor, a promotional factor in combination with UV, or coincidental.[2]
Ong and Brouwer (2012) reported a case of melanotan-associated melanoma in situ. The patient had used melanotan for tanning and developed melanoma in situ on a chronically sun-exposed site. The temporal association was noted, but causation could not be confirmed. The case is representative of the broader evidence pattern: each individual case has confounders, but the accumulation of cases in a population that uses a known MC1R agonist alongside UV exposure creates a biologically plausible risk signal that cannot be dismissed.[3]
Yassin et al. (2025) reported a case of oral mucosal malignant melanoma in a 22-year-old female who had used melanotan II nasal spray. Oral mucosal melanoma is extremely rare in young adults, making the temporal association with melanotan II use notable. The nasal spray delivery route means the peptide contacts oral and nasal mucosa directly, potentially providing local MC1R activation at the mucosal surface in addition to systemic effects.[4]
Eruptive Nevi
Multiple case reports have documented the rapid appearance of new melanocytic nevi (moles) following melanotan II use. This is pharmacologically expected: MC1R activation stimulates melanocyte proliferation. The clinical concern is that new nevi can be difficult to distinguish from early melanoma on clinical examination, and rapid development of multiple new pigmented lesions in an adult warrants dermatological surveillance.
Some reports have documented changes in pre-existing nevi (darkening, growth, altered shape) during melanotan II use. These changes mimic the ABCDE criteria used to screen for melanoma, creating diagnostic uncertainty.
Product Quality and Contamination
Mestria et al. (2021) conducted LC-HRMS (liquid chromatography-high resolution mass spectrometry) analysis of melanotan II and bremelanotide products purchased on the black market. The analysis identified variable purity, degradation products, and in some cases the wrong peptide entirely. This means users cannot know the actual dose, identity, or purity of what they are injecting.[5]
Janvier et al. (2018) reviewed the broader problem of falsified biotechnology drugs, including peptides sold through gray market channels. Peptide products purchased online have been found to contain bacterial endotoxins, aggregation products, incorrect peptide sequences, and sub-potent or super-potent concentrations. For melanotan II specifically, the absence of pharmaceutical-grade manufacturing standards means every injection carries contamination risk in addition to the pharmacological risks of the peptide itself.[6]
Other Documented Effects
Nausea and Gastrointestinal Effects
Nausea is the most commonly reported side effect of melanotan II, occurring in the majority of users at typical doses. This is consistent with central MC4R and MC3R activation, which modulate appetite and gastrointestinal motility. The nausea is typically transient (30-60 minutes post-injection) and is often the dose-limiting effect for new users.
Sexual Effects and Priapism
Melanotan II's effects on sexual arousal and erectile function were discovered incidentally during early clinical research. Hadley (2005) described how the melanocortin's sexual effects in both males and females were an unexpected finding during tanning research at the University of Arizona. These effects led to the development of bremelanotide (PT-141) as a selective formulation for sexual dysfunction.[7]
Priapism (prolonged, painful erection lasting more than four hours) has been reported with melanotan II use. This is a medical emergency requiring intervention to prevent permanent tissue damage. The risk is amplified by the common co-use of melanotan II with phosphodiesterase-5 inhibitors (sildenafil, tadalafil), which have a synergistic mechanism on erectile tissue.
Neuropsychiatric Effects
Melanotan II crosses the blood-brain barrier and activates MC3R and MC4R in the hypothalamus. Reported neuropsychiatric effects include facial flushing, yawning, stretching, and altered appetite. These effects reflect central melanocortin system activation and are pharmacologically expected.
The appetite suppression effect deserves separate attention. MC4R is the primary receptor mediating satiety in the hypothalamus, and melanotan II's appetite-suppressing effects have led some users to employ it as a weight loss agent. This is pharmacologically unsound: chronic MC4R activation for weight loss would carry the same hypertensive risk that has complicated every MC4R agonist drug development program. The approved MC4R agonist setmelanotide achieves weight loss without the blood pressure effect through apparent biased agonism, a receptor selectivity that melanotan II does not possess.
Injection Site and Infectious Risks
Because melanotan II is self-administered by subcutaneous injection, users face standard injection-related risks: local infection, abscess formation, and injection site reactions. More concerning, shared needle use and non-sterile injection practices have been reported in social settings where melanotan II is used recreationally. The peptide itself requires reconstitution from lyophilized powder using bacteriostatic water, and improper reconstitution or storage (including inadequate refrigeration) can introduce microbial contamination.
Interactions with Other Substances
The risk profile of melanotan II is compounded by frequent co-use with other substances. Common combinations include melanotan II with phosphodiesterase-5 inhibitors (increasing priapism risk), melanotan II with UV tanning bed exposure (amplifying melanoma risk through combined MC1R stimulation and DNA damage), and melanotan II with other gray market peptides whose interaction profiles are unknown. No pharmacokinetic interaction studies have been conducted for any of these combinations, and the safety profiles of these co-administration patterns remain entirely uncharacterized.
Why No Safety Data Exists
Melanotan II was synthesized at the University of Arizona in the early 1990s as a research tool for studying melanocortin receptor function and as a potential sunless tanning agent. Early clinical studies were conducted for tanning indications, but the program was never completed. The sexual arousal effects led to the development of bremelanotide (a linear derivative) rather than continued development of melanotan II itself.
Melanotan II entered the unregulated market in the mid-2000s, sold through online peptide vendors as a "research chemical" not intended for human use. This legal framing allows sale while avoiding regulatory requirements for safety testing, manufacturing standards, or adverse event reporting. The result is a widely used peptide with decades of human exposure but essentially no controlled safety data.
The scale of unregulated use is difficult to estimate. Surveys in some populations (particularly gym-goers and tanning enthusiasts in the UK and Australia) have found prevalence rates in the single-digit percentages. Social media promotion has expanded awareness. The absence of a pharmacovigilance system means that adverse events go unreported unless they result in emergency department visits serious enough to generate case reports in the medical literature. The true incidence of cardiovascular events, dermatological changes, and other adverse effects in the melanotan II-using population is unknown.
For the approved melanocortin drug bremelanotide's formal adverse event profile, see PT-141 (Bremelanotide) Adverse Events: What the FDA Approval Data Shows. For the broader melanocortin system and cardiovascular risk, see the cluster pillar Melanocortin Peptides and Blood Pressure: The Hypertensive Risk. For context on the wider regulatory landscape, see KPV Peptide: The Anti-Inflammatory Fragment from Alpha-MSH.
The Bottom Line
Melanotan II has never undergone controlled safety testing. Case reports document rhabdomyolysis, renal infarction, at least five melanoma cases, eruptive nevi, and priapism. Its non-selective activation of four melanocortin receptors produces cardiovascular risk (MC4R-driven sympathetic activation), dermatological risk (MC1R-driven melanocyte proliferation), and neurological effects (central MC3R/MC4R activation). Black market product quality is unreliable, with documented contamination and variable potency. The absence of safety data is not evidence of safety; it is evidence of an unmonitored experiment on a large population.